Induction of Antiviral Cytotoxic T Cells by Plasmacytoid Dendritic Cells for Adoptive Immunotherapy of Posttransplant Diseases
Article first published online: 29 AUG 2011
©Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 11, Issue 12, pages 2613–2626, December 2011
How to Cite
Aspord, C., Laurin, D., Richard, M.-J., Vie, H., Chaperot, L. and Plumas, J. (2011), Induction of Antiviral Cytotoxic T Cells by Plasmacytoid Dendritic Cells for Adoptive Immunotherapy of Posttransplant Diseases. American Journal of Transplantation, 11: 2613–2626. doi: 10.1111/j.1600-6143.2011.03722.x
- Issue published online: 28 NOV 2011
- Article first published online: 29 AUG 2011
- Received 01 May 2011, revised 15 July 2011 and accepted for publication 15 July 2011
Figure S1. HLA-A*0201+ pDCs induce virus-specific T-cell responses from HLA-A*0201+ healthy donors' PBMC with a high efficiency in vitro.
Figure S2. High quantity of virus-specific T cells are produced using the peptide-loaded pDC line.
Figure S3. The virus-specific T cells elicited by the pDC line display an MHC/peptide restricted activity without bystander allogeneic reactivity.
Figure S4. The expanded effector cells are cytotoxic in the setting of immunosuppression.
Figure S5. Response of HuPBL mice to vaccination by the peptide-loaded pDC line.
|AJT_3722_sm_SuppMat.doc||270K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.